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Introduction
Hepatitis C virus (HCV) is one of the most common causes in chronic infection resulting in liver cirrhosis and hepatocellular carcinoma (HCC). 1, 2 The associated complications, mortality, and need for liver transplantation are global problems. 3 Currently, the adjunction of new direct antiviral agents is changing the therapeutic approach in chronic HCV infection. 4 However, a significant number of patients are treated with the classic combination therapy of peginterferon and ribavirin where these new therapies cannot be afforded. 5e7 Consequently, to identify patients who are or are not good candidates for peginterferon plus ribavirin therapy is clinically important to avoid unnecessary treatments and minimize adverse effects. Several factors probably affecting response to peginterferon plus ribavirin therapy have been reported, including age, 5e8 interleukin (IL)28B polymorphisms, 7, 9, 10 liver fibrosis, 5e8 insulin resistance, 11 and viral factors, such as HCV load 12 and HCV variations. 10 Vitamin D is involved in the metabolism of skeleton as a systemic hormone but also has important roles in the regulation of host immune responses, fibrogenesis, and development of cancer through vitamin D receptor (VDR) . 13e15 Interestingly, a recent study showed that lower serum 25-hydroxylation (OH)D level was an independent negative risk factor for sustained virological response (SVR) to peginterferon plus ribavirin therapy for Caucasian patients with chronic hepatitis C. 16 Other studies have also reported that vitamin D supplementation may enhance the antiviral response of peginterferon plus ribavirin therapy, 17e19 but controversy still exists. 20, 21 In addition, VDR gene polymorphisms have been investigated in the context of some chronic liver diseases, such as chronic hepatitis B, primary biliary cirrhosis and autoimmune hepatitis. 22e24 Another study has demonstrated that bioactive 1,25-di-(OH)D3 enhanced the inhibitory effect of interferon-a on HCV replication, and has identified the VDR as a novel suppressor of interferon-a-induced signaling through the JakeSTAT pathway. 25 So far, there are limited data on the association between VDR polymorphisms and the antiviral response in chronic hepatitis C. In this study, we conducted a cohort of chronic hepatitis C patients in Asia receiving response-guided therapy with peginterferon plus ribavirin to clarify this issue.
Methods Patients
From August 2011 to July 2013, a total of 151 naive patients with chronic HCV genotype-1 infection who received peginterferon plus ribavirin therapy in single medical center in Taiwan were enrolled. All patients were seropositive for HCV antibody and HCV RNA, and all had exhibited elevated alanine aminotransferase levels. Patients were excluded if they were positive for serum hepatitis B surface antigen or anti-human immunodeficiency virus antibody, or exhibited other causes of hepatocellular injury (e.g., any history of alcoholism, autoimmune hepatitis, primary biliary cirrhosis, or treatment with hepatotoxic drugs). Clinical diagnosis of cirrhosis was based on repeated ultrasound findings suggestive of cirrhosis at least twice 3 months apart, supplemented with clinical criteria or other signs of portal hypertension. 26 In these 151 patients, we excluded 12 patients who did not fit the 80/80/80 adherence rule (< 80% of total peginterferon or ribavirin doses or < 80% of the total duration of therapy), with a final case number of 139.
Patients were treated according to the on-treatment response as follows: 24 weeks for patients achieving a rapid virological response (RVR, seronegativity of HCV RNA at 4 weeks of therapy); 48 weeks for those with an early virological response (EVR, at least a 2 e log10 decrease from baseline of serum HCV RNA at 12 weeks of treatment); and early termination (< 16 weeks) in those without an EVR. This protocol has been recommended by the National Health Insurance Bureau in Taiwan 
Qualitative and quantitative assay of HCV-RNA and HCV genotyping
Serum was prepared in a laminar flow bench and frozen at À70 C until use. Before treatment, qualitative detection of HCV RNA was performed by a standardized qualitative reverse transcriptionepolymerase chain reaction (PCR) assay (Amplicor; Roche Diagnostics, Branchburg, NJ, USA), using biotinylated primers for the 5 0 noncoding region. The lowest detection limit of this assay was 50 IU/mL. Serum HCV RNA levels were determined by COBAS TaqMan HCV Test (TaqMan HCV; Roche Molecular Systems Inc., Branchburg, NJ, USA; lower limit of detection: 15 IU/mL). Genotyping of HCV was performed by reverse hybridization assay (Inno-LiPA HCV II; Innogenetics N.V., Gent, Belgium) using the HCV-Amplicor products.
Detection of VDR and IL28B polymorphisms
The DNA was extracted from peripheral blood leukocytes using the Qiagen DNA isolation kit (Qiagen, Hilden, Germany). The VDR genotype was determined by PCR amplification and restriction length fragment polymorphisms as previously described. 25 For the detection of BsmI polymorphisms, a forward primer in exon 7 (5 0 -CAACCAA-GACTCAAGTACCGCGTCAGTGA-3 0 ) and a reverse primer in intron 8 (5 0 -AACCAGCGGAAGAGGTCAAGGG-3 0 ) were used. For the detection of ApaI and TaqI polymorphisms, a forward primer in exon 8 (5 0 -CAGAGCATGGACAGGGAGCAA-3 0 ) and a reverse primer in exon 9 (5 0 -GCAACTCCTCATGGCT-GAGGTCTC-3 0 ) were used. The PCR products for BsmI polymorphisms were 820 base pairs (bp), and for ApaI/TaqI polymorphisms they were 745 bp. The PCR mix contained 5 mL of each primer (10 pmol), 5 mL buffer, 1.5 mL MgCl 2 (50mM), 5 mL template DNA (50e100 ng), 5 mL dNTPs (2mM), Taq polymerase (MBI Fermentas, St. Leon-Rot, Germany) 2 mL, H 2 O 26.5 mL. The DNA template was denatured at 95 C for 2 minutes. A total of 40 cycles of PCR were performed, consisting of a denaturation step for 45 seconds at 94 C, an annealing step for 45 seconds at optimum temperature (67 C for ApaI/TaqI and 60 C for BsmI), and an extension reaction for 1 minute at 72 C. A final extension step at 72 C for 2 minutes was added after the last PCR cycle.
After amplification, the PCR products were digested with BsmI, ApaI, and TaqI endonucleases. Following restriction endonuclease digestion, genotyping was determined by ethidium bromide-UVB illumination of the fragments separated on gels of 2% agarose. The presence of BsmI, ApaI, or TaqI restriction sites was defined as the lower-case "b", "a", or "t", respectively, and the absence of the sites defined as the upper-case "B", "A", or "T". The BsmI restriction site resulted in two fragments (645 bp and 177 bp). Digestion with ApaI produced two fragments of 531 bp and 214 bp when the restriction site was present. Digestion with TaqI resulted in three fragments of approximately 205 bp, 290 bp, and 245 bp in the presence of TaqI polymorphic site, and in fragments of 245 bp and 495 bp in its absence.
IL28B variant rs12979860C>T was diagnosed from stored samples using direct sequencing (AmpliTaq gold DNA polymerase and BigDye terminator v1.1 cycle sequencing kit; Applied Biosystems, Warrington, Cheshire, UK). The PCR products were separated on an ABI3130 sequencer, and analyzed with SEQSCAPE 2.6 (Applied Biosystems
Statistical analysis
Continuous data are expressed as mean AE standard deviation, and the categorical data are expressed as number (percentage). Comparisons of differences in categorical date between groups were performed using the Chi-square test. Distributions of continuous variables were analyzed by the Student t test or ManneWhitney U test for the two groups where appropriate. Independent factors possibly affecting response to peginterferon plus ribavirin therapy were determined by stepwise multiple logistic regression analysis. A p value < 0.05 was considered statistically significant.
Results

Baseline characteristics
The basic demographic, virologic, and clinical features of the patients are shown in Table 1 . There were 71 men and 68 women, age 20e78 years (mean, 56 years). Fourteen percent (n Z 19) of patients had cirrhosis. Of these patients, 43 (31%) patients achieved a RVR, 87 (62.6%) achieved an EVR without RVR and nine (6.4%) had no EVR. The rates of SVR were 84% (n Z 36) of RVR patients, 44% (n Z 38) of EVR patients and 0% of non-EVR patients, respectively.
Comparison between bAt [CCA]-haplotype and other haplotypes
Of these patients, 76 (55%) carried bAt [CCA] haplotype. As shown in Table 2 , univariate analysis revealed that only HCV viral load was significantly different between these two groups. Figure 1 shows the association of VDR genotype with HCV load. We found that the carriage of ApaI CC genotype and TaqI AA genotype had significant higher viral load as compared to those with ApaI CA/AA type and TaqI AG type, respectively. Factors associated with sustained virological response to peginterferon plus ribavirin in a response-guided therapy As shown in Figure 2 , patients carrying the bAt [CCA] haplotype, ApaI CC genotype, and TaqI AA genotype had a trend in lower rate of achieving RVR and SVR. However, there were no significant associations of VDR gene polymorphisms with RVR and SVR achievement. By univariate analysis, the carriage of rs12979860 CC genotype, cirrhosis, higher platelet counts, and RVR were significantly associated with SVR. Stepwise logistic regression analysis revealed that rs12979860 CC genotype, higher platelet counts and RVR were independent predictors of SVR among these patients (Table 3) .
Discussion
Experimental evidence suggests the potential ability of vitamin D, through interaction with VDR, to regulate the host immune responses, fibrogenesis, and carcinogenesis. One of the common genetic variations of VDR gene is the bAt haplotype consisting of three adjacent restriction polymorphic sites, BsmI, ApaI, and TaqI. 27, 28 These genetic variations have been described as important modulators of several chronic liver diseases such as primary biliary cirrhosis and autoimmune hepatitis. 23, 24 In addition, our previous data showed that chronic hepatitis C patients with HCC had a higher frequency of ApaI CC genotype and bAt [CCA] haplotype than controls, and ApaI C polymorphism might be used as a molecular marker to predict the risk of HCC. 29 In this 30, 31 By contrast, we failed to find a significant association between VDR gene polymorphisms and treatment response, although there was a trend in lower rate of SVR among patients carrying bAt [CCA] haplotype, ApaI CC genotype, and TaqI AA genotype. These discordant results might be associated with the following facts. First, the C allele of the IL-28B rs12979860 C/T polymorphism is much more prevalent in Asians than in Caucasians, 32 and patients with IL28B favorable genotype attain a high SVR rate up to 70e80% in genotype-1 chronic hepatitis C patients. 10, 33 Therefore, it is possible that the high prevalence of the C allele results in blunting of the effect by vitamin D. This possibility is supported by the finding that a group of Caucasian patients with IL28B favorable genotype who had higher 25(OH)D concentrations had an SVR rate of 85.7%, whereas those with IL28B unfavorable genotype who also had higher 25(OH)D concentrations had an SVR rate of only 36.8%. 34 Second, it is well established that there are racial differences in the relations between the 25(OH)D concentrations, parathyroid hormone concentration, and calcium homeostasis. 35 Racial differences in vitamin D physiology or race-specific factors that modify the effects of vitamin D may affect the immune response to HCV. 36 Further studies with an increased number of cases are necessary to reach a firm conclusion.
A number of studies have evaluated an association between baseline 25 13, 38 In conclusion, the present study suggests a significant association of VDR bAt [CCA]-haplotype, ApaI CC genotype, and TaqI AA genotype with higher viral load in Asian patients with chronic HCV infection. However, VDR gene polymorphisms are not related to the response to peginterferon plus ribavirin therapy in our study population. The detailed molecular mechanisms deserve further investigation. 
